Know Labs Inc (KNW)

[slunj]

Know Labs Releases White Paper Detailing Experimental Results of their Bio-RFIDTM Technology

Seattle, WA. – January 16, 2019 – Know Labs, Inc. (OTCQB: KNWN) – a provider of diagnostic solutions, released today a white paper detailing the results of an experiment using their Bio-RFIDTM technology to detect varying blood-glucose levels in the human body. The experiment utilized a tissue phantom mimicking a blood/skin/muscle ratio of approximately 5%/10%/85% respectively to measure varying amounts of glucose in the blood. The experiment produced successful results with the sensor system showing strong signal response and linearity between the varying glucose levels. White paper co-author and Professor of Chemistry and Biochemistry at Bloomsburg University, Mark Tapsak, Ph.D., says of the technology, “The Know Labs Bio-RFID sensor represents a significant development in medicine, and I expect that their team will create disruptive products from this technology platform.”

The white paper states in part: “The Know Labs Bio-RFID glucose sensing system effectively uses RF spectroscopy to selectively measure glucose concentrations. This system will enable the creation of a wearable non-invasive blood glucose sensor for consumer and medical use.”

For a link to the white paper, Radio Frequency Spectroscopy using Know Labs Inc Bio-RFIDTM Sensor Technology, see: https://tinyurl.com/ya4y44td

The white paper was co-authored by Phil Bosua, CEO of Know Labs, and Mark Tapsak, Ph.D., who in addition to his professorial roles noted above is also Interim Assistant Vice President and Dean of Graduate Studies and Research at Bloomsburg University.